Ultragenyx Pharmaceutical Inc
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
RARE$15.43-0.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
During the three months ended March 31, 2025 the following directors and Section 16 officers adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Name and Title | Date Adopted | Aggregate Number of Shares of Common Stock to be Sold (Subject to Certain Conditions) | Plan End Date |
|---|---|---|---|
| Karah Parschauer,EVP, Chief Legal Officer and Corporate Affairs | March 11, 2025 | Up to 54,601 shares | March 3, 2026 |
| Emil D. Kakkis, M.D., Ph.D.President and CEO, Director | March 14, 2025 | Up to 100,000 shares | March 17, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.